Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06539806
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-18
Brief Title:
Clinical Study Evaluating the Effect of Losartan
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinical Study Evaluating the Effect of Losartan on Response Rate in Both Metastatic and Locally Advanced Pancreatic Cancer Patients
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The pancreas is two organs packaged into one The islets of Langerhans serve critical endocrine functions and the exocrine portion is a major source of enzymes that are essential for digestion
Pancreatic cancer PC is more commonly referred to as pancreatic infiltrating ductal adenocarcinoma in addition to being the second leading cause of cancer death in the United States after lung cancer in 2020
Whereas pancreatic cancer is the seventh cause of death from cancer in Asia in 2020 Although it is substantially less common than the other malignancies pancreatic carcinoma is near the top of the list of killers because it is a highly aggressive carry
Pancreatic cancer PC is more commonly referred to as pancreatic infiltrating ductal adenocarcinoma in addition to being the second leading cause of cancer death in the United States after lung cancer in 2020
Whereas pancreatic cancer is the seventh cause of death from cancer in Asia in 2020 Although it is substantially less common than the other malignancies pancreatic carcinoma is near the top of the list of killers because it is a highly aggressive carry
Detailed Description:
Pancreatic cancer has multi step carcinogenesis starting from Pancreatic Intra-ductal Neoplasia and ends with an invasive neoplastic lesionPancreatic cancer is most frequent in elder people the risk of developing pancreatic cancer goes up as people age
It is frequently found at an advanced stage which contributes to five-year survival rates of 2-9 ranking firmly the pancreatic cancer among all cancer sites in terms of prognostic outcomes for patients In addition it has a high trend to show nodal metastasis hepatic bone or pulmonary metastasis
Epidemiological data shows that pancreatic cancer is not very common but obvious it is one of the most neoplastic death-cause in the worldThe Renin angiotensin system RAS is an important regulator of the cardiovascular system that was identified in this system angiotensinogen is converted to angiotensin Ang I and then to Ang II by renin and angiotensin-converting enzyme ACE respectively
The Ang II activates the angiotensin type 1 receptor AT1R It has been suggested that RAS components are involved in the evolution of various cancers and tissues like prostate skin and pancreatic cancer In the pancreas they are considered to mediate growth and lead to carcinogenesis
High concentrations of Ang II have been reported together with up-regulated levels of AT1R in human with pancreatic cancer and malignant pancreatic tissues
AT1R is known to activate phosphatidylinositol-specific-phosphodiesterase C enzyme after being activated by Ang II to produce phosphate inositol and 2-acylglycerol which causes the entry of Ca2 into cells hence activating protein kinase C and mitogen-activated protein kinase MAPK
MAPK has an important role in cell proliferation Moreover studies show that Ang II induces Vascular endothelial growth factor VEGF expression which is the main growth factor involved in angiogenesis
Several studies have reported that RAS can increase the risk of metastasis in various cancers Building upon these findings RAS blockers may be expected to be beneficial in pancreatic cancer treatment
Losartan is a RAS inhibitor currently well-known to decrease blood pressure 10 It is demonstrated in several studies that Losartan can inhibit the effect of Ang II on cell proliferation and angiogenesis In PC its suggested that Losartan increases drug delivery to the tumor thus improving the chemotherapy effect
Furthermore it increase the efficacy of Nano-therapeutics in pancreatic cancer of mice through enhancing both interstitial and trans-vascular transport In another study it was found that Losartan raised DNA incorporation of Gemcitabine and enhanced its efficacy
Studies
Over the past two decades have provided important information on the potential therapeutic use of RAS blocker drugs in cancerExtensive preclinical data support the potential use of angiotensin II receptor blockers ARBs as anti-neoplastic agents in pancreatic cancer
It is frequently found at an advanced stage which contributes to five-year survival rates of 2-9 ranking firmly the pancreatic cancer among all cancer sites in terms of prognostic outcomes for patients In addition it has a high trend to show nodal metastasis hepatic bone or pulmonary metastasis
Epidemiological data shows that pancreatic cancer is not very common but obvious it is one of the most neoplastic death-cause in the worldThe Renin angiotensin system RAS is an important regulator of the cardiovascular system that was identified in this system angiotensinogen is converted to angiotensin Ang I and then to Ang II by renin and angiotensin-converting enzyme ACE respectively
The Ang II activates the angiotensin type 1 receptor AT1R It has been suggested that RAS components are involved in the evolution of various cancers and tissues like prostate skin and pancreatic cancer In the pancreas they are considered to mediate growth and lead to carcinogenesis
High concentrations of Ang II have been reported together with up-regulated levels of AT1R in human with pancreatic cancer and malignant pancreatic tissues
AT1R is known to activate phosphatidylinositol-specific-phosphodiesterase C enzyme after being activated by Ang II to produce phosphate inositol and 2-acylglycerol which causes the entry of Ca2 into cells hence activating protein kinase C and mitogen-activated protein kinase MAPK
MAPK has an important role in cell proliferation Moreover studies show that Ang II induces Vascular endothelial growth factor VEGF expression which is the main growth factor involved in angiogenesis
Several studies have reported that RAS can increase the risk of metastasis in various cancers Building upon these findings RAS blockers may be expected to be beneficial in pancreatic cancer treatment
Losartan is a RAS inhibitor currently well-known to decrease blood pressure 10 It is demonstrated in several studies that Losartan can inhibit the effect of Ang II on cell proliferation and angiogenesis In PC its suggested that Losartan increases drug delivery to the tumor thus improving the chemotherapy effect
Furthermore it increase the efficacy of Nano-therapeutics in pancreatic cancer of mice through enhancing both interstitial and trans-vascular transport In another study it was found that Losartan raised DNA incorporation of Gemcitabine and enhanced its efficacy
Studies
Over the past two decades have provided important information on the potential therapeutic use of RAS blocker drugs in cancerExtensive preclinical data support the potential use of angiotensin II receptor blockers ARBs as anti-neoplastic agents in pancreatic cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None